top of page

A Tale of Two Patients: Peter and Pietro

RESOURCES  >  MOST FAVORED NATION  >  A Tale of Two Patients: Peter and Pietro

Same diagnosis. Different countries.
Very different outcomes.

 

Peter lives in Philadelphia. Pietro lives in Pellaro, Italy. Both were diagnosed with the same stage of advanced prostate cancer in 2026 but have different access to treatment and outcomes because of where they live.

Peter

60 years old

Philadelphia, Pennsylvania

Peter notices his symptoms and gets checked by his doctor. Tests confirmed he has Stage 4 metastatic prostate cancer that had already spread to his lymph nodes.

​

He has private health insurance through work.

Pietro

60 years old

Pellaro, Italy

flag-italy.png

Pietro also noticed symptoms and went straight to his GP. After tests, he was given the same diagnosis as Peter: metastatic prostate cancer that had spread to his lymph nodes and bones.

​

He is a patient of Italy’s National Health Service (SSN).

Prostate cancer is the second most common cause of cancer in men globally  and ranks as the fifth leading cause of cancer mortality among men.  Over 1.46 million new cases were estimated worldwide in 2022.  About 1 in 8 American men will be diagnosed with prostate cancer during their lifetimes  , while in Italy this number is closer to 1 in 9.

​

Most men are diagnosed early, when survival is excellent. But when the cancer has spread, most often the bones and lymph nodes, it is considered stage 4 and is much more difficult to treat. Advanced disease is also becoming more common: late-stage diagnoses are rising in men of every age. In the U.S., 9% of prostate cancer cases are diagnosed at an advanced stage  , compared to 12.6% in Italy.

Getting a Diagnosis

 

Both Peter and Pietro noticed their symptoms on the same day. Here is how long it took each of them to get a diagnosis confirmed and start treatment:

Peter

Week 1

​

Sees his doctor, who orders a PSA test.

​

A PSA test is a blood test that measures prostate-specific antigen, a protein made by cells in the prostate gland, both normal and cancerous ones. Small amounts circulate in the blood of all men, but higher levels can signal a problem. Based on his results, Peter is referred to a urologist— all within one week.

Weeks 2–3

​

Peter receives a formal urologist evaluation, prostate MRI, biopsy, and his initial staging.

 

A biopsy is the definitive test used to diagnose prostate cancer, while imaging helps determine whether the cancer has spread.

Weeks 4–11

​

Meets his oncology team, finalizes his treatment plan, and begins treatment. The average wait time in the U.S. from diagnosis to treatment is 51 days.

Total: About 11 weeks from noticing his symptoms to starting treatment.

Pietro

Week 1

​

Sees his practicioner, who requests a PSA test and refers him to a urologist through the national health service.

Week 2–3

 

Pietro also receives a urologist evaluation, prostate MRI, and biopsy. Italy's 2024 Society of Urology guidance recommends a stepwise pathway that generally uses multiparametric MRI to determine whether biopsy is warranted. The guidance also specifically notes that MRI accessibility and waiting lists should be considered because access can affect the diagnostic pathway.

Weeks 4–16+

 

Treatment planning and initiation. An Italian study found a 93-day median interval from biopsy-confirmed diagnosis to first treatment, with patients living in Southern Italy more likely to face waits exceeding 90 days.

Total: 16+ weeks — more than a month longer than Peter.

Research shows that for advanced prostate cancer, delays in starting the right targeted treatment are linked to significantly lower survival. Every week matters. A 2020 analysis examined treatment timing in high-risk prostate cancer treated with radiation and hormone replacement therapy. It found that initiating treatment more than 74 days after diagnosis was associated with a 21% higher risk of death.

Treatment: Where the Paths Split

 

This is where Peter and Pietro's experiences diverge further, as their access to innovative medicines is not the same. In Italy, men with metastatic prostate cancer wait about 22 months longer for access to the same new treatments as their peers in the U.S.

Starting Treatment
(First-line Therapy)

Peter

A new drug combination approved in the U.S. in July 2026, Pluvicto in combination with hormone replacement therapies, as first-line treatment.

 

This is currently the most effective first-line treatment available for his type of cancer anywhere in the world. About 90% of eligible U.S. patients are within 30 miles of an authorized Pluvicto treatment site.

Pietro

A combination of hormone replacement therapies, an androgen-deprivation therapy combined with an androgen-receptor pathway inhibitor.

​

Pluvicto + hormone therapy is not yet available on the SSN as a first-line therapy. In the U.S., Pluvicto was first approved for use as a third-line treatment in 2022.   Over the past 4 years, it has gradually transitioned to an effective first-line treatment. Italy only approved Pluvicto as a third-line treatment in 2025, and access remains limited.

Second-line Therapy

Peter may eventually need a second-line treatment if his cancer progresses, but Pluvicto is designed to delay that progression. In clinical trials, Peter’s first-line treatment reduced progression or death by 28% in the initial analysis. With longer follow-up, the reduction reached 33%.

Pietro has already missed out on the stronger first-line treatment Peter received. Now, he gets progressive chemotherapy with an aggressive drug known as docetaxel.

Third-line Therapy

If Peter's cancer eventually progresses, his next treatment would depend on factors such as how his cancer responds, his previous treatments, genetic testing, and the location and extent of his disease. Options can include chemotherapy, targeted therapies, or other radiopharmaceuticals.

 

He may also be eligible for clinical trials testing the next generation of treatments.

Only now, as a third-line treatment, can Pietro get access to Pluvicto. However, unlike in the U.S., there are very few hospitals in Italy that are equipped to administer Pluvicto. The nearest treatment center to Pietro is over 120 miles away, adding to the burden of his prognosis and forcing him to find local housing while he receives treatment.

What Does This Mean for Peter and Pietro?

Peter is receiving Pluvicto at the beginning of his treatment journey, when his cancer is less aggressive. This means more time spent in good health. More time to spend with his family and friends. And importantly, more time to potentially benefit from the latest clinical trials and new treatment innovations.

​

By the time Pietro receives Pluvicto, his cancer may be more resistant to the drug, and his overall health has significantly deteriorated, reducing the likelihood of successful treatment. Additionally, geographic barriers force Pietro to undergo a stressful move during treatment. It is unlikely that Pietro will qualify for clinical trials due to his declining health.

​

Peter and Pietro are fictional, but the gaps in treatment access and outcomes they represent are real.

Learn more about what “Most Favored Nation” pricing means for the U.S.

Sources

i. Wang, Le, et al. “Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019.” Frontiers in Public Health, vol. 10, Feb. 2022, p. 811044. PubMed Central, https://doi.org/10.3389/fpubh.2022.811044.

 

ii. Zhou, Yuxin, et al. “A Global Review and Perspective on Prostate Cancer Survival: Findings from Survival Studies of Cancer Registration Data.” Journal of the National Cancer Center, vol. 6, no. 2, Apr. 2026, pp. 175–84. DOI.org (Crossref), https://doi.org/10.1016/j.jncc.2026.01.005.

 

iii. “ACS Study Finds Prostate Cancer Incidence and Mortality Rates Rising in Many Low- and Middle-Income Countries.” American Cancer Society MediaRoom, https://pressroom.cancer.org/releases?item=1385. Accessed 12 Oct. 2026.

​

iv. Key Statistics for Prostate Cancer | Prostate Cancer Facts. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html. Accessed 8 Oct. 2026.

​

v. Key Statistics for Prostate Cancer | Prostate Cancer Facts. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html. Accessed 8 Oct. 2026.

​

vi. Centers for Disease Control and Prevention. “U.S. Cancer Statistics Prostate Cancer Stat Bite.” U.S. Cancer Statistics, U.S. Department of Health and Human Services, 1 June 2026, https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer-stat-bite.html. Accessed 12 Oct. 2026.

​

vii. Crocetti, Emanuele, et al. “The Burden of Prostate Cancer and Metastatic Prostate Cancer in Italy in 2024.” European Journal of Cancer Prevention, vol. 34, no. 5, Sept. 2025, pp. 387–91. DOI.org (Crossref), https://doi.org/10.1097/CEJ.0000000000000960.

viii. Onukwugha, Eberechukwu, et al. “Specialist Visits and Initiation of Cancer-Directed Treatment among a Large Cohort of Men Diagnosed with Prostate Cancer.” Urologic Oncology: Seminars and Original Investigations, vol. 35, no. 4, Apr. 2017, p. 150.e17-150.e23. DOI.org (Crossref), https://doi.org/10.1016/j.urolonc.2016.11.012.

 

ix. The Pros-IT CNR Study Group, et al. “The Waiting Time for Prostate Cancer Treatment in Italy: Analysis from the PROS-IT CNR Study.” Minerva Urology and Nephrology, vol. 74, no. 1, Mar. 2022. DOI.org (Crossref), https://doi.org/10.23736/S2724-6051.20.03925-9.

 

x. “FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advancing Potential New Standard of Care across Metastatic Disease.” Novartis, https://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease. Accessed 8 Oct. 2026.

​

xi. Treatment Center Locator | PLUVICTO. https://us.pluvicto.com/treatment-center-locator. Accessed 8 Oct. 2026.

​

xii. “Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) FDA Approval History.” Drugs.Com, https://www.drugs.com/history/pluvicto.html. Accessed 8 Oct. 2026.

​

xiii. AIFA Board of Directors Approves the Reimbursability of 13 Medicines. https://www.aifa.gov.it/en/-/cda-aifa-approva-rimborsabilita-di-13-farmaci. Accessed 8 Oct. 2026.

​

xiv. “PSMAddition Data Show Novartis PluvictoTM Delays Progression to End-Stage Prostate Cancer.” Novartis, https://www.novartis.com/news/media-releases/psmaddition-data-show-novartis-pluvictotm-delays-progression-end-stage-prostate-cancer. Accessed 8 Oct. 2026.

Stay informed about PFCD, sign up for updates:

Thank you. Your email has been submitted.

By providing my mobile number I consent to receive informational text messages from Partnership to Fight Chronic Disease. Message frequency may vary. Msg & Data rates may apply. Donations will not be solicited. Text STOP to opt-out. Text HELP for help. For additional information, please see our Terms & Conditions and Privacy Policies. Mobile and opt-in data will not be shared with third parties.

© Copyright 2025. Partnership to Fight Chronic Disease

bottom of page